FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3165649279> ?p ?o ?g. }

• W3165649279 endingPage "2113" @default.
• W3165649279 startingPage "2101" @default.
• W3165649279 abstract "Sodium-glucose co-transporter-2 (SGLT-2) inhibitors have been shown to have beneficial effects on various cardiovascular (CV) outcomes in patients with type 2 diabetes (T2D) in primary prevention and in those with a high CV risk profile. However, the mechanism(s) responsible for these CV benefits remain elusive and unexplained. The aim of the DAPAHEART study will be to demonstrate that treatment with SGLT-2 inhibitors is associated with greater myocardial insulin sensitivity in patients with T2D, and to determine whether this improvement can be attributed to a decrease in whole-body (and tissue-specific) insulin resistance and to increased myocardial perfusion and/or glucose uptake. We will also determine whether there is an appreciable degree of improvement in myocardial-wall conditions subtended by affected and non-affected coronary vessels, and if this relates to changes in left ventricular function. The DAPAHEART trial will be a phase III, single-center, randomized, two-arm, parallel-group, double-blind, placebo-controlled study. A cohort of 52 T2D patients with stable coronary artery disease (without any previous history of myocardial infarction, with or without previous percutaneous coronary intervention), with suboptimal glycemic control (glycated hemoglobin [HbA1c] 7–8.5%) on their current standard of care anti-hyperglycemic regimen, will be randomized in a 1:1 ratio to dapagliflozin or placebo. The primary outcome is to detect changes in myocardial glucose uptake from baseline to 4 weeks after treatment initiation. The main secondary outcome will be changes in myocardial blood flow, as measured by 13N-ammonia positron emission tomography/computed tomography (PET/CT). Other outcomes include cardiac function, glucose uptake in skeletal muscle, adipose tissue, liver, brain and kidney, as assessed by fluorodeoxyglucose (FDG) PET-CT imaging during hyperinsulinemic-euglycemic clamp; pericardial, subcutaneous and visceral fat, and browning as observed on CT images during FDG PET-CT studies; systemic insulin sensitivity, as assessed by hyperinsulinemic-euglycemic clamp, glycemic control, urinary glucose output; and microbiota modification. SGLT-2 inhibitors, in addition to their insulin-independent plasma glucose-lowering effect, are able to directly (substrate availability, fuel utilization, insulin sensitivity) as well as indirectly (cardiac after-load reduction, decreased risk factors for heart failure) affect myocardial functions. Our study will provide novel insights into how these drugs exert CV protection in a diabetic population. EudraCT No. 2016-003614-27; ClinicalTrials.gov Identifier: NCT03313752." @default.
• W3165649279 created "2021-06-07" @default.
• W3165649279 creator A5004298689 @default.
• W3165649279 creator A5015781135 @default.
• W3165649279 creator A5029130187 @default.
• W3165649279 creator A5031505042 @default.
• W3165649279 creator A5035542322 @default.
• W3165649279 creator A5040337251 @default.
• W3165649279 creator A5048437639 @default.
• W3165649279 creator A5054373143 @default.
• W3165649279 creator A5064268494 @default.
• W3165649279 creator A5067950881 @default.
• W3165649279 creator A5071134404 @default.
• W3165649279 creator A5076259830 @default.
• W3165649279 creator A5081762535 @default.
• W3165649279 creator A5083126449 @default.
• W3165649279 date "2021-05-26" @default.
• W3165649279 modified "2023-10-18" @default.
• W3165649279 title "Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial" @default.
• W3165649279 cites W1526927233 @default.
• W3165649279 cites W1877394668 @default.
• W3165649279 cites W1904336231 @default.
• W3165649279 cites W1989061211 @default.
• W3165649279 cites W2012085370 @default.
• W3165649279 cites W2023731159 @default.
• W3165649279 cites W2024878386 @default.
• W3165649279 cites W2033591884 @default.
• W3165649279 cites W2034597681 @default.
• W3165649279 cites W2039918892 @default.
• W3165649279 cites W2045918150 @default.
• W3165649279 cites W2053365438 @default.
• W3165649279 cites W2066061382 @default.
• W3165649279 cites W2071544399 @default.
• W3165649279 cites W2071792752 @default.
• W3165649279 cites W2072203364 @default.
• W3165649279 cites W2072312403 @default.
• W3165649279 cites W2128606426 @default.
• W3165649279 cites W2134850479 @default.
• W3165649279 cites W2136145230 @default.
• W3165649279 cites W2138173919 @default.
• W3165649279 cites W2143121088 @default.
• W3165649279 cites W2146264128 @default.
• W3165649279 cites W2147663252 @default.
• W3165649279 cites W2148328779 @default.
• W3165649279 cites W2152758124 @default.
• W3165649279 cites W2155799150 @default.
• W3165649279 cites W2158666727 @default.
• W3165649279 cites W2164705414 @default.
• W3165649279 cites W2253712555 @default.
• W3165649279 cites W2275107142 @default.
• W3165649279 cites W2315104804 @default.
• W3165649279 cites W2331274940 @default.
• W3165649279 cites W2343975335 @default.
• W3165649279 cites W2412800896 @default.
• W3165649279 cites W2416348735 @default.
• W3165649279 cites W2498901811 @default.
• W3165649279 cites W2562329777 @default.
• W3165649279 cites W2570926474 @default.
• W3165649279 cites W2626446274 @default.
• W3165649279 cites W2900413769 @default.
• W3165649279 cites W2916912835 @default.
• W3165649279 cites W2921017081 @default.
• W3165649279 cites W2950601110 @default.
• W3165649279 cites W2974260792 @default.
• W3165649279 cites W3081830235 @default.
• W3165649279 cites W3089283105 @default.
• W3165649279 cites W3100542962 @default.
• W3165649279 cites W3111650805 @default.
• W3165649279 cites W3129290046 @default.
• W3165649279 cites W4212888272 @default.
• W3165649279 cites W4237542254 @default.
• W3165649279 cites W2039700830 @default.
• W3165649279 doi "https://doi.org/10.1007/s13300-021-01083-1" @default.
• W3165649279 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8266960" @default.
• W3165649279 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34037951" @default.
• W3165649279 hasPublicationYear "2021" @default.
• W3165649279 type Work @default.
• W3165649279 sameAs 3165649279 @default.
• W3165649279 citedByCount "3" @default.
• W3165649279 countsByYear W31656492792022 @default.
• W3165649279 countsByYear W31656492792023 @default.
• W3165649279 crossrefType "journal-article" @default.
• W3165649279 hasAuthorship W3165649279A5004298689 @default.
• W3165649279 hasAuthorship W3165649279A5015781135 @default.
• W3165649279 hasAuthorship W3165649279A5029130187 @default.
• W3165649279 hasAuthorship W3165649279A5031505042 @default.
• W3165649279 hasAuthorship W3165649279A5035542322 @default.
• W3165649279 hasAuthorship W3165649279A5040337251 @default.
• W3165649279 hasAuthorship W3165649279A5048437639 @default.
• W3165649279 hasAuthorship W3165649279A5054373143 @default.
• W3165649279 hasAuthorship W3165649279A5064268494 @default.
• W3165649279 hasAuthorship W3165649279A5067950881 @default.
• W3165649279 hasAuthorship W3165649279A5071134404 @default.
• W3165649279 hasAuthorship W3165649279A5076259830 @default.
• W3165649279 hasAuthorship W3165649279A5081762535 @default.
• W3165649279 hasAuthorship W3165649279A5083126449 @default.
• W3165649279 hasBestOaLocation W31656492791 @default.
• W3165649279 hasConcept C126322002 @default.

• next